Abstract
Background: Sodium-glucose cotransporter 2 inhibitors are a new class of medications that have been proven to improve both glycemic control and cardio-renal outcomes. The knowledge, attitude, and perception toward their prescriptions in Jazan, Saudi Arabia, are still unknown.
Objective: The study aimed to measure the level of knowledge and attitude toward sodium-glucose cotransporter 2 inhibitors prescription among physicians in the Jazan region, Saudi Arabia.
Methods: Data analysis was performed using Statistical Package for the Social Sciences, SPSS 23rd version. Frequency and percentages were used to display categorical variables. Minimum, maximum, mean, and standard deviation were used to test numerical variables. Independent t-test and ANOVA test were both utilized to test the factors associated with knowledge and attitude toward the use of SGLT-2 inhibitors.
Results: A total of 65 participants were included in the study. 26.2% had a low knowledge level, 30.8% had a moderate knowledge level, and 43.1% had a high knowledge level of sodium-glucose cotransporter 2 inhibitors. 9.2% had a low attitude level, 43.1% had a moderate attitude level, and 47.7% had a high attitude level toward sodium-glucose cotransporter 2 inhibitors. Age, professional status, years of experience, and specialty were significantly associated with attitude but not with the knowledge of sodium-glucose cotransporter 2 inhibitors prescription.
Conclusion: While the study cohort scored high in the knowledge and attitude domains of the survey, a large proportion failed to answer very essential questions in type 2 diabetes management. An educational awareness program needs to be carried out to strengthen the physicians’ knowledge of SGLT2 inhibitors prescription.
[1]
Vallianou NG, Geladari EV, Kounatidis D, et al. Diabetes mellitus in the era of climate change. Diabetes Metab 2021; 47(4): 101205.
[http://dx.doi.org/10.1016/j.diabet.2020.10.003] [PMID: 33127474]
[http://dx.doi.org/10.1016/j.diabet.2020.10.003] [PMID: 33127474]
[2]
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-81.
[http://dx.doi.org/10.1016/j.diabres.2018.02.023] [PMID: 29496507]
[http://dx.doi.org/10.1016/j.diabres.2018.02.023] [PMID: 29496507]
[3]
Naeem Z. Burden of Diabetes Mellitus in Saudi Arabia. Int J Health Sci 2015; 9(3): V-VI.
[http://dx.doi.org/10.12816/0024690] [PMID: 26609301]
[http://dx.doi.org/10.12816/0024690] [PMID: 26609301]
[4]
Alotaibi A, Perry L, Gholizadeh L, Al-Ganmi A. Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: An overview. J Epidemiol Glob Health 2017; 7(4): 211-8.
[http://dx.doi.org/10.1016/j.jegh.2017.10.001] [PMID: 29110860]
[http://dx.doi.org/10.1016/j.jegh.2017.10.001] [PMID: 29110860]
[5]
Bahtiyar G, Gutterman D, Lebovitz H. Heart failure: A major cardiovascular complication of diabetes mellitus. Curr Diab Rep 2016; 16: 116.
[6]
Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328(23): 1676-85.
[http://dx.doi.org/10.1056/NEJM199306103282306] [PMID: 8487827]
[http://dx.doi.org/10.1056/NEJM199306103282306] [PMID: 8487827]
[7]
Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: A review on recent drug based therapeutics. Biomed Pharmacother 2020; 131: 110708.
[http://dx.doi.org/10.1016/j.biopha.2020.110708] [PMID: 32927252]
[http://dx.doi.org/10.1016/j.biopha.2020.110708] [PMID: 32927252]
[8]
Gupta P, Bala M, Gupta S, et al. Efficacy and risk profile of antidiabetic
therapies: Conventional vs traditional drugs—A mechanistic
revisit to understand their mode of action. Pharmacol Res 2016; 113(Pt A): 636-74.
[http://dx.doi.org/10.1016/j.phrs.2016.09.029] [PMID: 27697646]
[http://dx.doi.org/10.1016/j.phrs.2016.09.029] [PMID: 27697646]
[9]
Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014; 104(3): 297-322.
[http://dx.doi.org/10.1016/j.diabres.2014.02.014] [PMID: 24735709]
[http://dx.doi.org/10.1016/j.diabres.2014.02.014] [PMID: 24735709]
[10]
Gronda E, Lopaschuk GD, Arduini A, et al. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Can J Physiol Pharmacol 2022; 100.
[11]
Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev 2021; 26: 623-42.
[12]
Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A sys-tematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7(11): 845-54.
[http://dx.doi.org/10.1016/S2213-8587(19)30256-6] [PMID: 31495651]
[http://dx.doi.org/10.1016/S2213-8587(19)30256-6] [PMID: 31495651]
[13]
Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 2018; 39(5): 363-70.
[http://dx.doi.org/10.1093/eurheartj/ehx511] [PMID: 29020355]
[http://dx.doi.org/10.1093/eurheartj/ehx511] [PMID: 29020355]
[14]
Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46(6): 462-72.
[http://dx.doi.org/10.1159/000484633]
[http://dx.doi.org/10.1159/000484633]
[15]
Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics. Nephrol Dial Transplant 2020; 35(10): 1700-11.
[http://dx.doi.org/10.1093/ndt/gfaa234] [PMID: 32862232]
[http://dx.doi.org/10.1093/ndt/gfaa234] [PMID: 32862232]
[16]
Ciardullo S, Trevisan R, Perseghin G. Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines. Pharmacol Res 2021; 166: 105530.
[http://dx.doi.org/10.1016/j.phrs.2021.105530] [PMID: 33675963]
[http://dx.doi.org/10.1016/j.phrs.2021.105530] [PMID: 33675963]
[17]
Adhikari R, Heyward J, Alexander GC, Blaha M. Cardiologist use of SGLT2 inhibitors and glp-1 receptor agonists since release of favora-ble cardiovascular outcomes trials: A national study. J Am Coll Cardiol 2021; 77(18 (S1)): 1468-8.
[http://dx.doi.org/10.1016/S0735-1097(21)02826-6]
[http://dx.doi.org/10.1016/S0735-1097(21)02826-6]
[18]
Milder TY, Stocker SL, Baysari M, Day RO, Greenfield JR. Prescribing of SGLT2 inhibitors in primary care: A qualitative study of Gen-eral Practitioners and Endocrinologists. Diabetes Res Clin Pract 2021; 180: 109036.
[http://dx.doi.org/10.1016/j.diabres.2021.109036] [PMID: 34481911]
[http://dx.doi.org/10.1016/j.diabres.2021.109036] [PMID: 34481911]
[19]
Beshyah SA, Hafidh K, Shaikh TG. Evolving physicians’ perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2020; 168: 108389.
[http://dx.doi.org/10.1016/j.diabres.2020.108389] [PMID: 32858101]
[http://dx.doi.org/10.1016/j.diabres.2020.108389] [PMID: 32858101]
[20]
Slater TA, Drozd M, Palin V, et al. Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coro-nary syndromes: A survey of cardiologists’ attitudes and practice. Eur Heart J Cardiovasc Pharmacother 2020; 6(3): 194-6.
[http://dx.doi.org/10.1093/ehjcvp/pvz058] [PMID: 31702003]
[http://dx.doi.org/10.1093/ehjcvp/pvz058] [PMID: 31702003]
[21]
Somaili M, Oraibi O, Mohrag M, et al. Baseline characteristics associated with sodium-glucose cotransporter inhibitor prescriptions in type 2 diabetic patients in jazan,Saudi Arabia. Cureus 2022; 14(4): e24284.
[http://dx.doi.org/10.7759/cureus.24284] [PMID: 35602773]
[http://dx.doi.org/10.7759/cureus.24284] [PMID: 35602773]
[22]
Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibi-tors and GLP-1 receptor agonists, 2013–2018. Diabetes Care 2020; 43(4): 921-4.
[http://dx.doi.org/10.2337/dc19-1943] [PMID: 32041899]
[http://dx.doi.org/10.2337/dc19-1943] [PMID: 32041899]
[23]
Hofer F, Kazem N, Richter B, et al. Prescription patterns of sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes in patients with diabetes mellitus and heart failure. Cardiovasc Drugs Ther 2022; 36(3): 497-504.
[http://dx.doi.org/10.1007/s10557-021-07234-7] [PMID: 34342791]
[http://dx.doi.org/10.1007/s10557-021-07234-7] [PMID: 34342791]
[24]
Khunti K, Jabbour S, Cos X, et al. Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab 2022; 24(7): 1187-96.
[http://dx.doi.org/10.1111/dom.14684] [PMID: 35238129]
[http://dx.doi.org/10.1111/dom.14684] [PMID: 35238129]
[25]
Jeong SJ, Lee SE, Shin DH, Park IB, Lee HS, Kim KA. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: A real-world study. BMC Nephrol 2021; 22(1): 177.
[http://dx.doi.org/10.1186/s12882-021-02381-3] [PMID: 33990175]
[http://dx.doi.org/10.1186/s12882-021-02381-3] [PMID: 33990175]
[26]
Takeuchi M, Ogura M, Inagaki N, Kawakami K. Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: Hypothetical intervention using parametric g-formula modeling. BMJ Open Diabetes Res Care 2022; 10(3): e002636.
[http://dx.doi.org/10.1136/bmjdrc-2021-002636] [PMID: 35675951]
[http://dx.doi.org/10.1136/bmjdrc-2021-002636] [PMID: 35675951]
[27]
Singhal P, Liu G, Miller S, Latz M, Motiani M, Van Herle H. Clinical practice patterns and attitudes about prescribing SGLT2 inhibitors at a single-center academic safety-net hospital. J Am Coll Cardiol 2021; 77(18 (S1)): 1543-3.
[http://dx.doi.org/10.1016/S0735-1097(21)02901-6]
[http://dx.doi.org/10.1016/S0735-1097(21)02901-6]
[28]
McCoy IE, Han J, Montez-Rath ME, Chertow GM, Rhee JJ. Patient and provider characteristics associated with sodium–glucose cotrans-porter 2 inhibitor prescription in patients with diabetes and proteinuric chronic kidney disease. Clin Diabetes 2020; 38(3): 240-7.
[http://dx.doi.org/10.2337/cd19-0087] [PMID: 32699472]
[http://dx.doi.org/10.2337/cd19-0087] [PMID: 32699472]
[29]
Vasquez-Rios G, Nadkarni GN. SGLT2 inhibitors: Emerging roles in the protection against cardiovascular and kidney disease among dia-betic patients. Int J Nephrol Renovasc Dis 2020; 13: 281-96.
[http://dx.doi.org/10.2147/IJNRD.S268811] [PMID: 33149657]
[http://dx.doi.org/10.2147/IJNRD.S268811] [PMID: 33149657]
[30]
De Nicola L, Gabbai FB, Garofalo C, Conte G, Minutolo R. Nephroprotection by SGLT2 inhibition: Back to the future? J Clin Med 2020; 9(7): 2243.
[http://dx.doi.org/10.3390/jcm9072243] [PMID: 32679744]
[http://dx.doi.org/10.3390/jcm9072243] [PMID: 32679744]
[31]
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: Pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure association of the european society of cardiology. Eur J Heart Fail 2019; 21(10): 1169-86.
[http://dx.doi.org/10.1002/ejhf.1531] [PMID: 31129923]
[http://dx.doi.org/10.1002/ejhf.1531] [PMID: 31129923]
[32]
Faulkenberg KD, Williams JB, Isaacs DM, West LM. Practical considerations and opportunities for SGLT2 inhibitor prescription in heart failure. Curr Treat Options Cardiovasc Med 2020; 22(10): 36.
[http://dx.doi.org/10.1007/s11936-020-00825-x]
[http://dx.doi.org/10.1007/s11936-020-00825-x]
